Glutathione Studies — What the Research Shows

Glutathione — γ-L-glutamyl-L-cysteinyl-glycine, GSH in its reduced form and GSSG as the disulfide — is a tripeptide, and an ordinary constituent of every nucleated cell at low millimolar concentrations. J. de Rey-Pailhade first described it in yeast in 1888 as “philothion”; Frederick Gowland Hopkins isolated and named it in 1921. This article covers how cells build glutathione, what the GSH/GSSG redox couple measures, the enzymes that depend on it, what depletion models and rodent tissue studies report, how laboratories quantify it, and where the human evidence runs out. It is a companion to our NAD+ research summary, because the NADPH that keeps glutathione reduced belongs to the same pyridine-nucleotide pool.

Research-use-only context. This article summarizes published third-party scientific literature — the large majority of it conducted in cultured cells or animal models. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. American Peptides products are sold strictly for in vitro laboratory research and are not for human or veterinary use.

What glutathione is

Most peptides link their residues through α-peptide bonds. Glutathione breaks that rule at its first linkage: glutamate is joined to cysteine through its side-chain γ-carboxyl, hence γ-glutamyl-cysteinyl-glycine. The γ-glutamyl bond has a practical consequence: ordinary intracellular peptidases do not recognise it, so glutathione is long-lived inside the cell, and only γ-glutamyl transpeptidase, anchored on the outer cell surface, cleaves it. The reactive centre is the cysteine thiol. When two glutathione molecules each give up an electron their thiols join into a disulfide, producing one GSSG; glutathione reductase reverses the reaction using NADPH. Glutathione has no receptor; its targets are peroxides, electrophiles and the oxidised thiols of other proteins.

Biosynthesis is well mapped. A 2013 review by Lu in Biochimica et Biophysica Acta describes a two-step, ATP-dependent process confined to the cytosol. Glutamate cysteine ligase (GCL), made of a catalytic (GCLC) and a modifier (GCLM) subunit, forms γ-glutamylcysteine and is rate-limiting; glutathione synthetase (GS) adds glycine. The review names two determinants of how much glutathione a cell can make — cysteine supply and GCL activity — and notes that GCL subunits and GS are regulated at multiple levels, often in coordination, by transcription factors including Nrf2 acting through the antioxidant response element, AP-1 and NF-κB.¹ Glutathione is a pool whose size tracks cysteine availability and the transcriptional state of the cell.

What cell and tissue studies report

The GSH/GSSG couple as a redox readout

A 2001 review by Schafer and Buettner in Free Radical Biology and Medicine set out to make “redox state” quantitative. The authors define the redox environment of a compartment through the Nernst equation and argue that the glutathione disulfide/glutathione couple (GSSG/2GSH), the most abundant redox couple in a cell, is the most useful single indicator. Its half-cell reduction potential appears to track biological status: roughly −240 mV in proliferating cells, −200 mV in differentiating cells and −170 mV in cells undergoing apoptosis.³ One feature matters for experimental design: because two GSH yield one GSSG, the potential depends on [GSH]²/[GSSG], so absolute concentration moves it even at a constant ratio.

The enzymes that use glutathione

Glutathione peroxidases use GSH to reduce hydrogen peroxide and lipid hydroperoxides, producing GSSG. Glutathione S-transferases conjugate GSH to electrophilic xenobiotics so they can be exported. Glutathione reductase closes the loop, regenerating GSH from GSSG at the expense of NADPH. A 2009 review by Marí and colleagues in Antioxidants & Redox Signaling frames the first two as the main routes by which mitochondrial glutathione counteracts hydrogen peroxide, lipid hydroperoxides and xenobiotics.⁴ The reductase step is where glutathione biology meets NAD(P) biology: without NADPH, GSSG accumulates no matter how much GSH a cell has made.

Depletion models: buthionine sulfoximine

Much of what is known about glutathione in cells comes from removing it. The tool is buthionine sulfoximine (BSO), described in 1979 by Griffith and Meister in the Journal of Biological Chemistry. BSO inhibited γ-glutamylcysteine synthetase (GCL) about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine, without detectably inhibiting glutamine synthetase, and the authors proposed it as a tool for inhibiting glutathione synthesis in experimental systems.² Because BSO blocks synthesis without adding an oxidant, it separates two otherwise tangled questions: what happens when glutathione is low, and what happens when an oxidant is present. Cultured cells exposed to BSO lose cytosolic glutathione over hours and are the standard model for sensitisation to peroxides, electrophiles and mitochondrial stress.

The mitochondrial pool

The Marí review concentrates on one compartment. Mitochondria are the primary intracellular site of oxygen consumption and the major source of reactive oxygen species, and the authors describe mitochondrial glutathione (mGSH) as the main line of defence for the mitochondrial redox environment. They report that numerous pathological settings — hypoxia, ischaemia–reperfusion, aging, liver and neurological conditions — are characterised by a consistent decrease in mGSH, which may sensitise mitochondria to further insults.⁴ The review also develops the point that mitochondria do not synthesise glutathione but import it from the cytosol, so the mitochondrial pool depends on transport as well as on GCL. See also What is mitochondrial health? and the SS-31 research summary.

How glutathione is measured

The most widely used method is the enzymatic recycling assay described in a 2006 Nature Protocols paper by Rahman, Kode and Biswas. GSH reduces 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman’s reagent) to a yellow product read at 412 nm; the GSSG formed is recycled to GSH by glutathione reductase and NADPH, so colour develops at a rate proportional to total glutathione. The authors report a detection limit of 0.103 nM in a 96-well plate, a procedure of about 15 minutes, and applicability to blood, body fluids, tissue and cell extracts.⁵ HPLC methods separate GSH, GSSG and mixed disulfides directly and are preferred when the ratio is the endpoint. The principal pitfall is pre-analytical: GSH oxidises readily in solution, so samples must be stabilised promptly, and a reagent standard is checked by HPLC purity and free-thiol content for the same reason.

What animal models report

Two threads of rodent work are relevant. The first is depletion. In the same 1979 paper, Griffith and Meister reported that mice exposed to BSO showed kidney glutathione reduced to less than 20% of control values, a larger decrease than they had seen with prothionine sulfoximine, and that BSO did not produce the convulsions associated with methionine sulfoximine.²

The second is aging. A 2011 study by Rebrin, Forster and Sohal in Free Radical Biology and Medicine compared C57BL/6 and DBA/2 mice, whose lifespans respond differently to caloric restriction: only C57BL/6 is extended. The authors measured GSH, GSSG and protein-mixed disulfides in skeletal muscle and liver at 6 and 24 months. In freely fed animals of both strains, GSSG and protein-mixed disulfides rose and the GSH:GSSG ratio fell with age. Caloric restriction prevented those changes in C57BL/6 but not DBA/2 mice, and enhanced GCL activity only in C57BL/6.⁶ The strain in which the shift was prevented is the strain that lived longer. It is correlative, and it is a mouse finding.

Where the human evidence stops

The human literature divides into tissue-sample observation and small intervention studies, and reviewers are cautious about both. Lang and colleagues reported in 1992 in the Journal of Laboratory and Clinical Medicine on 169 healthy, ambulatory adults aged 20 to 94. Using the 20- to 39-year-olds as reference, they found the proportion of subjects with low erythrocyte glutathione rose significantly with age, most clearly in the 60- to 79-year-old group, whose mean was 17% below reference.⁷ It is cross-sectional — older individuals with lower values, not individuals declining over time — and it measures blood, not tissue.

The central intervention question has been whether glutathione taken by mouth reaches the circulation intact at all, given that γ-glutamyl transpeptidase in the gut wall and liver hydrolyses the γ-glutamyl bond. The largest controlled study is Richie and colleagues’ 2015 randomised, double-blinded, placebo-controlled trial in the European Journal of Nutrition, which the authors introduce by stating that the efficacy of oral glutathione in humans had not been established. Fifty-four non-smoking adults were followed for six months at two exposure levels. Blood glutathione rose from baseline at one, three and six months; at six months the higher-exposure group showed increases of roughly 30–35% in erythrocytes, plasma and lymphocytes and 260% in buccal cells, and the oxidised-to-reduced ratio in whole blood fell. Levels returned to baseline after a one-month washout.⁸ It remains one trial, in 54 people, with biomarker rather than functional endpoints. Whether the result reflects absorption of intact glutathione or of its amino acids followed by resynthesis is not resolved by the data.

Three further things need stating plainly. Glutathione is not approved by the FDA as a drug for any indication. The intervention literature concerns oral products in healthy volunteers, and nothing in it transfers to glutathione supplied as a laboratory reagent, which is characterised by identity, purity and thiol content and has no human outcome data of its own. And the reviewers cited here are explicit that the links between glutathione status and aging biology are incompletely understood.^1,4

What is not established

Whether the age-related fall in erythrocyte glutathione seen in cross-sectional human samples⁷ reflects decline within individuals, or occurs in human tissues other than blood.
Whether the GSH:GSSG shift that tracks lifespan in mice⁶ is causal, and whether anything comparable operates in human tissue.
Whether intact glutathione crosses the human gut wall in meaningful amounts, or whether the increases reported in one trial⁸ arise from precursor amino acids and resynthesis.
Which redox-potential thresholds proposed from cultured cells³ hold in intact tissue, and how mitochondrial glutathione import is regulated in human cells.⁴

Frequently Asked Questions

Is glutathione a peptide?

Yes. Glutathione is a tripeptide of glutamate, cysteine and glycine. Its first linkage is a γ-glutamyl bond rather than a standard α-peptide bond, which protects it from ordinary intracellular peptidases; only γ-glutamyl transpeptidase cleaves it.

What does the GSH/GSSG ratio tell a researcher?

It is a proxy for the redox environment of the compartment sampled. Schafer and Buettner estimated half-cell reduction potentials of about −240 mV in proliferating, −200 mV in differentiating and −170 mV in apoptotic cells.

Why is buthionine sulfoximine used in glutathione research?

BSO inhibits glutamate cysteine ligase, the rate-limiting enzyme of glutathione synthesis, without adding an oxidant and without inhibiting glutamine synthetase. Griffith and Meister described it in 1979, and it remains the standard way to produce glutathione-depleted cells and rodent tissues.

Is glutathione approved by the FDA?

No. Glutathione is not approved by the FDA as a drug for any indication, and the human literature is limited to cross-sectional samples and small biomarker trials. American Peptides supplies glutathione strictly for in vitro research.

Citations

Lu SC (2013). “Glutathione synthesis.” Biochim Biophys Acta. 1830(5):3143–3153. PMID 22995213
Griffith OW, Meister A (1979). “Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine).” J Biol Chem. 254(16):7558–7560. PMID 38242
Schafer FQ, Buettner GR (2001). “Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple.” Free Radic Biol Med. 30(11):1191–1212. PMID 11368918
Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC (2009). “Mitochondrial glutathione, a key survival antioxidant.” Antioxid Redox Signal. 11(11):2685–2700. PMID 19558212
Rahman I, Kode A, Biswas SK (2006). “Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method.” Nat Protoc. 1(6):3159–3165. PMID 17406579
Rebrin I, Forster MJ, Sohal RS (2011). “Association between life-span extension by caloric restriction and thiol redox state in two different strains of mice.” Free Radic Biol Med. 51(1):225–233. PMID 21530646
Lang CA, Naryshkin S, Schneider DL, Mills BJ, Lindeman RD (1992). “Low blood glutathione levels in healthy aging adults.” J Lab Clin Med. 120(5):720–725. PMID 1431500
Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE (2015). “Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.” Eur J Nutr. 54(2):251–263. PMID 24791752

Research Access Verification

Glutathione Research: What the Studies Actually Show

What glutathione is